TransCelerate BioPharma Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • TransCelerate BioPharma's estimated annual revenue is currently $20.5M per year.(i)
  • TransCelerate BioPharma's estimated revenue per employee is $201,000

Employee Data

  • TransCelerate BioPharma has 102 Employees.(i)
  • TransCelerate BioPharma grew their employee count by 6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is TransCelerate BioPharma?

TransCelerate BioPharma Inc. was launched in 2012 as a non-profit organization to improve the health of people around the world by accelerating and enhancing the research and development of innovative new therapies. Our mission is to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. Our membership is made up of 20+ of the world’s most innovative and successful biopharmaceutical organizations who provide their best talent to collaborate and develop solutions to overcome industry inefficiencies. Our growing portfolio of Initiatives develops practical solutions to overcome inefficiencies in clinical trials and is drawn from the combined expertise of our members, and working collaboratively with health authorities, industry groups, research organizations and academia. To learn more, or to contact TransCelerate, please explore our website.

keywords:N/A

N/A

Total Funding

102

Number of Employees

$20.5M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.9M1079%N/A
#2
$29.2M108-2%N/A
#3
$25.9M114-3%N/A
#4
$38.1M1180%$13.4M
#5
$20.6M125N/AN/A